



# On the Record: Stakeholders on How PBMs Deliver for Patients, Employers & Taxpayers

## U.S. Chamber of Commerce

"Given the complexity of health care markets, any hasty or haphazard effort to regulate PBMs likely would have the unintended consequences of limiting competition, harming consumers, and raising prices..."

## Citizens Against Government Waste

"...Restrictions on PBMs would be anticompetitive and raise prices. Other government and private sector studies have drawn similar conclusions..."

## Rep. Lloyd Doggett (D-TX), Chair and Founder of the House Affordable Prescription Drug Task Force

"After years of denying that there was a drug pricing problem, [drug companies] began almost daily pointing their finger at their favorite boogeyman: pharmacy benefit managers... PBMs are the only part of the supply chain that is pushing back on monopoly drug prices."

## Senator Ted Cruz (R-TX)

"Previously conducted robust economic analysis of PBMs...found that PBMs benefit consumers by lowering drug prices. They also found disclosure regulations...could increase prices on consumers' drug and health plans."

## Congressman Eric Burlison (R-MO)

"Within health care, we have completely removed any cost transparency or decision-making from patients. The more that we continue to remove any negotiating ability, the more that the costs are going to go up. ... But if you eliminate the ability to group and create formularies and be able to determine what prescriptions are preferred, then you're eliminating their ability to negotiate with pharmaceutical companies altogether. And I think this will be a dangerous step to allowing pharmaceutical [costs] to skyrocket."

## U.S. Department of Labor Office of Inspector General Audit

"...The audits noted OWCP lacked a pharmacy benefit manager to help contain costs..."

## Senator Rand Paul (R-KY)

"Why are [businesses and labor unions] choosing a PBM? Do you think they want higher prices? And if a PBM is gouging, then why don't they go to another PBM? There's like 70 some-odd PBMs. And yet we've got in our heads somehow, we're going to forbid this... instead of trying to unravel the complications we put on the market, what we're asking is to ban certain contracts."

## Frederick Isasi, Executive Director, Families USA

"Some drug costs are lower than they otherwise would be because of PBMs – and pharmaceutical corporations have taken particular aim at PBMs because of their role in negotiating a better price."

## Alex Brill, Senior Fellow, American Enterprise Institute

"[PBM] rebates end up having a threefold benefit to the healthcare system: they lower health insurance premiums for beneficiaries, they drive price competition among drug manufacturers, and they help facilitate PBMs' clinical tools...Claims that PBM rebates are a cause of increasing drug prices seem to be unfounded."

## Americans for Tax Reform

"...PBMs are already transparent. They provide extensive information to patients including information on premiums, out-of-pocket costs, and coverage and provide employers and other health plan sponsors detailed information about rebates, fees, and payments and provide."

## Casey Mulligan, The University of Chicago

"Reducing competition among PBMs, even if unintentional, could cost up to \$48 billion per year. These are the risks of disclosure to be weighed against a potential reward of transferring one or two billion dollars annually from PBMs to other market participants."

## Benjamin Rome, Internist and Health Policy Researcher, Harvard Medical School

"PBMs are the only thing we have to lower brand-name drug prices and prevent the drug industry from charging whatever they want."